CGBIO (CEO Hyun Seung Yu), a leader in bio-regenerative medicine, announced on the 14th its participation, alongside Innosys (CEO Ju Mi Chung), at the North American Spine Society 2024 (NASS) held in Chicago, USA from September 25th to 28th. They showcased biportal endoscopic spinal fusion surgery using their cutting-edge spinal surgery products, demonstrating Korea’s advanced medical technology.
NASS 2024 is the world’s largest annual conference where spine specialists and industry experts from around the world gather to share clinical experiences and the latest technologies in spine treatment. ‘Surgical Stadium’, one of NASS’s official programs, is a live demonstration of next-generation surgical techniques selected through rigorous screening. CGBIO’s “Biportal Endoscopic TLIF with Expandable cage & rhBMP-2” was chosen as one of the five procedures in competition with global conglomerates.
Participating in the Surgical Stadium were Professor Jin Sung Kim from The Catholic University of Korea Seoul St. Mary’s Hospital, Professor Don Y. Park from UCI Health, Dr. Dong Hwa Heo from Cheongdam Harrison Hospital, Professor Ho Jin Lee from Chungnam National University Hospital, Dr. Chul Woong Park from Daejeon Woori Hospital, and Professor Seong Lee from Severance Hospital.
Additionally, CGBIO provided an opportunity to directly experience and learn the spinal endoscopy surgical method independently developed in Korea through the ‘Innovation Lab’ program, responding to continuous requests from American and South American medical professionals eager to learn Korea’s advanced biportal endoscopic spinal fusion surgery. The Innovation Lab, focusing on skill-based education, was led by Professor Ho Jin Lee and Dr. Chul Woong Park.
Both the Surgical Stadium and Innovation Lab were crowded with foreign spine specialists, reaffirming both the high status of Korea’s world-class biportal endoscopic spinal fusion surgical techniques and the intense interest of spine specialists worldwide. Notably, the Innovation Lab was attended by numerous Innosys users from South America, the United States, and Canada, with applicants reaching 2.4 times the capacity, confirming high demand for additional training. Accordingly, CGBIO and Innosys are preparing continuous education and training programs in the United States.
At the Surgical Stadium and Innovation Lab programs, it was emphasized that when both the Novosis Putty injectable bone substitute based on bone morphogenetic protein (rhBMP-2) and the Excender height-expandable cage are used together in spine surgery, synergistic effects can be achieved from the unique characteristics of both products. Excender is designed to easily inject Novosis Putty, the bone graft material, maximizing the effect of spinal fusion while minimizing spinal damage and restoring disc height and angle.
Furthermore, CGBIO operated a joint booth with Innosys at this event to promote their products. They focused on discovering new distributors by introducing representative products in the spine and surgical fields, including ▲CGDERM Spinkle, an allogeneic dermis-based biopatch ▲NOVOSIS bone substitute ▲ALLOMIX bone substitute ▲Excender expandable cage ▲Colonnade minimally invasive screw. Innosys introduced ▲Unispace, a cervical surgical cage, ▲Innoverse screw for spinal fixation scheduled for release within the year, and various medical devices used in biportal spine endoscopic surgery.
CGBIO conducted a clinical kick-off meeting for Novosis Putty, establishing a network between domestic and international researchers and laying the groundwork for entering advanced markets. Additionally, they introduced their spinal endoscopy surgical items to key opinion leaders (KOLs) in collaboration with Innosys’s U.S. branch and provided education on endoscopy standards and their products, establishing a foundation for these KOLs to act as local speakers in the field of spinal endoscopic surgery in the future.
Hyun Seung Yu, CEO of CGBIO, said, “Showcasing CGBIO’s product capabilities and advanced surgical techniques at the world’s largest spine society meeting is meaningful. We will continue to strengthen our competitiveness in the global market by making company-wide efforts based on differentiated technology.”
▲ Professor Ho Jin Lee and Dr. Chul Woong Park conducting surgical technique education at the Innovation Lab.
